# Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

> **NCT04476979** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 453 (actual)

## Conditions studied

- Coronavirus Infection
- SARS (Severe Acute Respiratory Syndrome)
- Virus Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Respiratory Tract Infections
- Respiratory Tract Disease

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04476979
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-08-11
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2024-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476979, "Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04476979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*